ERBB2 and breast carcinoma: Following the pivotal phase III trials EMILIA [4] and TH3RESA [5], which established T-DM1 as a standard therapeutic option for HER2-positive breast cancer, this single-center retrospective analysis offers valuable real-world data on treatment effectiveness.